Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$2.41
+6.6%
$2.82
$1.87
$12.60
$4.28M-0.022.00 million shs156,678 shs
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$1.56
-2.5%
$1.74
$1.20
$3.35
$5.09M0.87112,440 shs16,144 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.22136,765 shsN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$3.15
-1.5%
$3.39
$2.20
$5.27
$4.93M2.3153,368 shs11,123 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
+6.64%+6.17%-11.56%-33.79%-45.54%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
-2.50%-10.34%-15.22%-16.80%-91.10%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%-50.00%0.00%0.00%0.00%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-1.53%-11.24%-14.49%+0.35%-14.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
1.171 of 5 stars
0.02.00.04.32.41.70.0
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
0.8296 of 5 stars
0.03.00.00.01.40.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
0.00
N/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.00
N/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$1.33M3.42N/AN/A($11.37) per share-0.21
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$4.30M1.18N/AN/A$0.70 per share2.23
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$2.50M1.94N/AN/A$3.89 per share0.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
-$7.90M-$19.96N/AN/A-647.29%N/A-50.13%8/18/2025 (Estimated)
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
-$3.08MN/A0.00N/A-85.56%-63.93%-31.42%N/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$3.96M-$2.38N/AN/AN/A-142.10%-57.31%-49.30%8/12/2025 (Estimated)

Latest NPHC, CPHI, ALBT, and XBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$0.64N/AN/AN/A$0.48 millionN/A
5/13/2025Q1 2025
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A-$1.43N/A-$1.43N/AN/A
5/13/2025Q1 2025
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$0.72-$0.59+$0.13-$0.59$0.52 million$0.59 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/AN/AN/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A
0.19
0.19
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.22
0.79
0.26
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/A
8.20
8.20

Institutional Ownership

CompanyInstitutional Ownership
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
1.42%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
15.12%

Insider Ownership

CompanyInsider Ownership
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
37.30%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
17.32%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
14.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
51.89 million1.19 millionNot Optionable
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
2503.26 million15.92 millionNot Optionable
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
41.54 million1.32 millionNot Optionable

Recent News About These Companies

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avalon GloboCare stock logo

Avalon GloboCare NASDAQ:ALBT

$2.41 +0.15 (+6.64%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$3.60 +1.19 (+49.38%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

China Pharma stock logo

China Pharma NYSE:CPHI

$1.56 -0.04 (-2.50%)
Closing price 08/5/2025 03:59 PM Eastern
Extended Trading
$1.58 +0.02 (+1.28%)
As of 08/5/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

Xenetic Biosciences stock logo

Xenetic Biosciences NASDAQ:XBIO

$3.15 -0.05 (-1.53%)
Closing price 08/5/2025 03:51 PM Eastern
Extended Trading
$3.14 -0.02 (-0.51%)
As of 08/5/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.